Loading...
•
Jun 30, 2025
Cytek Biosciences Q2 2025 Earnings Report
Cytek Biosciences reported its financial results for the second quarter ended June 30, 2025.
Key Takeaways
Cytek Biosciences experienced a slight revenue decrease of 2% in Q2 2025 compared to the previous year, reaching $45.6 million. Despite a challenging macro environment, the company saw steady growth in FSP unit placements and recurring revenue, which grew by 16%. Net loss improved significantly, from $10.4 million in Q2 2024 to $5.6 million in Q2 2025.
Total revenue for Q2 2025 was $45.6 million, a 2% decrease year-over-year.
The total installed base of Cytek instruments expanded to 3,295, with 146 units added in Q2 2025.
Recurring revenue, comprising service and reagent revenues, increased by 16% compared to Q2 2024.
Net loss for Q2 2025 was $5.6 million, an improvement from a $10.4 million net loss in Q2 2024.
Revenue by Segment
Forward Guidance
Cytek Biosciences has narrowed its full-year 2025 revenue guidance to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates.
Positive Outlook
- Continued focus on expanding the global installed base of instruments.
- Parallel goal of growing recurring revenue through service and reagent businesses.
- Plans to strengthen market leadership through innovation, including new product launches like the Cytek Aurora Evo system.
- Expectation for the instrument market to recover over time.
- Poised to emerge in an even stronger position with a focus on longer-term growth drivers.
Challenges Ahead
- Challenging macro environment persists.
- Revenue guidance range includes potential for a 2% decrease compared to 2024.
- Assumes no change from current currency exchange rates, implying potential vulnerability to currency fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...